Edwards

FTC Takes Action: Lawsuit Filed to Block Edwards Lifesciences’ $945M Acquisition of JenaValve Over Antitrust Concerns

by

Washington, D.C. — The Federal Trade Commission is taking legal action against Edwards Lifesciences over its plans to acquire JenaValve, raising concerns about potential antitrust violations in the medical device industry. The FTC argues that this acquisition could stifle competition in the market for transcatheter aortic valve replacement devices designed for treating aortic regurgitation. In July 2024, Edwards Lifesciences announced intentions to purchase JenaValve and JC Medical, two notable developers in the transcatheter aortic valve replacement sector. Edwards completed the acquisition of JC Medical in August, paying approximately $320 million, and the FTC warns that … Read more

Class Action Lawsuit Filed Against Edwards Lifesciences for Alleged Securities Fraud – Investors Alerted

by

A class action lawsuit alleging securities fraud has been initiated against Edwards Lifesciences Corporation, spotlighting potential legal consequences for the prominent medical device company. Filed in a federal court, the lawsuit accuses the company of misleading investors about its financial prospects, particularly in relation to its heart valve products, which significantly influence its revenue stream. Edwards Lifesciences, based in Irvine, California, is a global leader in the development of innovative treatments for structural heart disease and critically ill patients. The lawsuit claims that the company provided optimistic projections that were allegedly not supported by the … Read more

Rosen Law Firm Announces Key Deadline in Edwards Lifesciences Securities Class Action – Investors Urged to Act by December 13

by

New York — The Rosen Law Firm, recognized globally for defending investor rights, is currently notifying investors of the impending lead plaintiff deadline on December 13, 2024, in the class action lawsuit against Edwards Lifesciences Corporation. This lawsuit pertains to all individuals who acquired securities in Edwards between February 6, 2024, and July 24, 2024. These investors might be eligible for monetary recovery via a contingency fee arrangement, requiring no out-of-pocket fees. Edwards Lifesciences, listed under NYSE: EW, is primarily involved through its innovations in patient-focused medical innovations, including the critical Transcatheter Aortic Valve Replacement … Read more

Deadline Alert: Rosen Law Firm Reminds Edwards Lifesciences Investors of Upcoming Lead Plaintiff Deadline in Securities Class Action Lawsuit

by

NEW YORK — Rosen Law Firm, renowned for championing global investor rights, has issued a reminder about the impending lead plaintiff deadline of December 13, 2024, for those who acquired securities from Edwards Lifesciences Corporation during the period of February 6, 2024, to July 24, 2024. This deadline is crucial for investors who believe they have suffered losses due to potential misinformation by Edwards Lifesciences regarding their financial forecasts and product performance. Investors who have bought Edwards securities within this specified period may be eligible for compensation without the necessity of any out-of-pocket fees or … Read more